Community Oncology Alliance Launches Oncology Fellows Task Force

Read original article HERE. Oncology Fellows Task Force Will Guide COA’s Efforts to Educate Future Workforce on Practicing in the Community Setting WASHINGTON, D.C., UNITED STATES, May 17, 2022 /EINPresswire.com/ — The Community Oncology Alliance (COA) announced today the creation of an Oncology Fellows Task Force to help guide the organization’s efforts to engage oncology […]

Read More

No Good Deed Goes Unpunished—How PBM Mandates Increase Practice Variability

Written by Jeff Patton, MD. See original article HERE. Jeff Patton, MD, CEO and board member at OneOncology, dived into the controversial role that pharmacy benefit managers (PBMs) play in formulary decision marking and how PBMs impact biosimilar utilization. In August 2019, OneOncology became one of the first to make available to practices biosimilars to […]

Read More

Beyond Immunotherapy: New Targeted Agents for Advanced NSCLC

Read original article HERE. The advent of PD-1 and PD-L1 checkpoint inhibitors has changed the treatment landscape of advanced non–small cell lung cancer (NSCLC), but only approximately 20% of patients treated with immunotherapy will be alive at 5 years. According to Melissa L. Johnson, MD, Director, Lung Cancer Research, Sarah Cannon Research Institute at Tennessee […]

Read More

OneOncology’s Arrowsmith Looks Forward to Real-time Dynamics in Clinical Pathways

Read original article HERE. Across OneOncology, says Edward Arrowsmith MD, MPH, clinical pathways offer a vehicle for physicians to agree on best practices and to implement them across the network. Early this year, Arrowsmith became medical director for Clinical Pathways, OneOncology. The role of clinical pathways is evolving, said Edward Arrowsmith, MD, MPH, who in […]

Read More

Dr. Stephen Schleicher on Future Advances in Value-Based Care

Watch the video HERE. Stephen Schleicher, MD, MBA, chief medical officer of Tennessee Oncology, talks about lessons learned from the Oncology Care Model (OCM) and Medicare that are being used to innovate toward value-based care. As the Oncology Care Model (OCM) ends and we wait for the next model, there is a lot of innovation […]

Read More